Three Peaks Capital Management’s Charles River Laboratories CRL Stock Holding History

Three Peaks Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-27,691	Closed	-$3.67M	–	99
2019 Q3	$3.67M	Buy	27,691 +3,503	+14%	+$470K	1.05%	47
2019 Q2	$3.43M	Sell	24,188 -1,196	-5%	-$162K	0.99%	51
2019 Q1	$3.69M	Sell	25,384 -134	-0.5%	-$17.6K	1.09%	43
2018 Q4	$2.89M	Sell	25,518 -10,537	-29%	-$1.32M	0.91%	40
2018 Q3	$4.85M	Sell	36,055 -3,425	-9%	-$423K	0.99%	28
2018 Q2	$4.43M	Buy	39,480 +31,102	+371%	+$3.36M	0.89%	51
2018 Q1	$894K	Buy	+8,378	New	+$903K	0.15%	96

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Three Peaks Capital Management's CRL Position: Q4 2019 in Review

Three Peaks Capital Management sold out of Charles River Laboratories (CRL) in Q4 2019, closing a stake of 27,691 shares — an estimated $3.67M sold.

Three Peaks Capital Management first reported a position in CRL in Q1 2018 and held it in 7 quarters. The position peaked at $4.85M in Q3 2018. 413 funds tracked by Wall St. Rank hold CRL as of Q4 2019.

Three Peaks Capital Management reported no remaining Charles River Laboratories position as of Q4 2019 after selling out during the quarter.
Three Peaks Capital Management sold 27,691 Charles River Laboratories shares in Q4 2019, an estimated $3.67M.
Three Peaks Capital Management first reported a position in Charles River Laboratories in Q1 2018 and held it in 7 quarters.
Three Peaks Capital Management's Charles River Laboratories position peaked at $4.85M in Q3 2018.
413 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2019.

Based on Three Peaks Capital Management's 13F filing for Q4 2019, filed 17 Jan 2020.